Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | STK3 | Q13188 | 2/20 | 0.40 |
| ▸ | STK26 | Q9P289 | 2/20 | 0.40 |
| ▸ | MST1 | P26927 | 1/20 | 0.40 |
| ▸ | STK4 | Q13043 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13761529 | 1.00 | PDE4D (0.46) | PDE4DMTORTRPV1PIK3CALRRK2 | |
| SCHEMBL3878523 | 0.94 | TRPV1 (0.45) | PDE4DMTORTRPV1LRRK2PIK3CD | |
| SCHEMBL3881506 | 0.92 | TRPV1 (0.45) | MTORTRPV1PIK3CA | |
| SCHEMBL3880037 | 0.90 | TRPV1 (0.50) | MTORTRPV1PIK3CA | |
| SCHEMBL3879649 | 0.90 | TRPV1 (0.50) | MTORTRPV1PIK3CA | |
| SCHEMBL3877163 | 0.89 | TRPV1 (0.49) | MTORTRPV1PIK3CA | |
| SCHEMBL3883483 | 0.89 | SYK (0.46) | PDE4DMTORTRPV1LRRK2PIK3CD | |
| SCHEMBL13761528 | 0.89 | SYK (0.46) | PDE4DMTORTRPV1LRRK2PIK3CD | |
| SCHEMBL3878595 | 0.89 | TRPV1 (0.45) | MTORTRPV1PIK3CA | |
| SCHEMBL3890136 | 0.87 | TRPV1 (0.53) | MTORTRPV1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | GPR174, GPR68, PPARG | PDE4D 695/4885MTOR 2949/4885TRPV1 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.